The benefit of clinical benefit: A European perspective

Annals of Oncology

Volumn 7, Issue 4, 1996, Pages 333-334

  Verweij, J ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; EDITORIAL; FOLLOW UP; HEALTH CARE QUALITY; MEDICAL DECISION MAKING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR REGRESSION;

EID: 0030056689     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010596     Document Type: Editorial

References (7)

1. WHO Handbook for Reporting Results of Cancer Treatment 1979 WHO Geneva
2. Verweij J. Pinedo H.M. Systemic treatment of advanced or meta-static soft tissue sarcomas Pinedo H.M. Verweij J. Suit H.D. Soft Tissue Sarcomas: New Developments in the Multidisciplinary Approach to Treatment 1991 Kluwer Academic Publishers Boston 75 91
3. Rothenberg M.L. Moore M.J. Cripss M.C. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreatic cancer Ann Oncol 7 4 1996 347 353 (this issue)
4. Vantongelen K. Steward W. Blackledge G. EORTC joint ventures in quality control: Treatment-related variables and data acquisition in chemotherapy trials Eur J Cancer 27 1991 201 207
5. Steward W. Vantongelen K. Verweij J. Chemotherapy administration and data collection in an EORTC collaborative group — can we trust the results? A study of the EORTC Soft Tissue and Bone Sarcoma Group Eur J Cancer 29A 1993 943 947
6. Brundage M.D. Pater J.L. Zee B. Assessing the reliability of two toxicity scales: Implications for interpreting toxicity data J Natl Cancer Inst 85 1993 1138 1148
7. De Boer M. Djontono J. Visser B. Patient perception of the side effects of chemotherapy: The influence of the introduction of 5-HT3 antagonists Eur J Cancer 29A Suppl 6 1993 S264